Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of use thereof
US11904053B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2020 |
| Grant date | Feb 20, 2024 |
| Priority date | — |
| Expiry date | Nov 29, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.